Advances in Hematology / 2010 / Article / Tab 3

Review Article

Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas

Table 3

Studies on High-Dose Therapy and Allogeneic Stem Cell Transplantation in PTCL.
(a) Retrospective data

AuthorYear AgeHistologiesIPIPrevious autoSCTRegimen (MA versus RIC)Status at TxDFS/EFS/ PFSOSTRM/NRMFollowup (months)GVHD

Feyler et al. [40]20071828PTCLu 50%
T-cell leuk. 28%
ALCL 17%
CTCL 6%
0/1   33%
≥2   66%
11%100% MANo data33% (3 y)39% (3 y) 57Acute GVHD °3/4: 28%
Ext. chronic GVHD: 6%

Murashige et al. [51]20052838NK/T 79%
Blastic NK 11%
NK-leukemia 11%
No data32%82% versus 18%CR 57%34% (2 y)40% (2 y)29%34Acute GVHD °3/4: 29%
Ext. chronic GVHD: 11%

Hamadani et al. [52]20081443PTCLu 36%
AITL 28%
ALCL 14%
NK/T 14%
Other 7%
aaIPI
0/1   57%
2/3   42%
14%57% versus 43%CR 21%
PR 35%
31% (3 y)35% (3 y) 34Acute GVHD °3/4: 21%
Chronic GVHD: 50%

Le Gouill et al. [53]20087736PTCLu 35%
ALCL 35%
AITL 14%
Other 16%
0/1   61%
≥2   32%
Unknown 6%
25%74% versus 26%CR 40%
PR 30%
53% (5 y)57% (5 y) 43Acute GVHD °3/4: 21%

Kyriakou et al. [54]20094548AITL 100%No data33%56% versus 45%CR 27%
PR 22%
53% (3 y)64% (3 y) 29Acute GVHD °3/4: 11%
Ext. chronic GVHD: 24%

(b) Prospective data

AuthorYear AgeHistologiesIPIPrevious autoSCTRegimen (MA versus RIC)Status at TxDFS/EFS/ PFSOSTRM/NRMFollowup (months)GVHD

Corradini et al. [55]20041741PTCLu 53%
ALCL 24%
AITL 24%
aaIPI
0/1   24%
2/3   76%
47%100% RICCR 12%
PR 71%
64% (3 y)81% (3 y)6%28Acute GVHD 12%
Ext. chronic GVHD: 6%

Wulf et al. [56]20051045PTCLu 40%
ALCL 30%
AITL 20%
T-PLL 10%
No data20%100% RICCR 10%
PR 50%
60% (7 m)70% (7 m)30%7Acute GVHD 10%
Ext. chronic GVHD: 50%

at day 100.